CXM Stock Chart & Stats
€318.00
€5.00(0.99%)
At close: 4:00 PM EST
€318.00
€5.00(0.99%)
Day’s Range― - ―
52-Week Range€316.00 - €438.00
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€5.70B
Enterprise Value€6.01B
Total Cash (Recent Filing)€16.86M
Total Debt (Recent Filing)€236.93M
Price to Earnings (P/E)26.4
Beta0.33
Next Earnings
Jul 28, 2026EPS Estimate
4.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)18.39
Shares Outstanding13,274,104
10 Day Avg. Volume1
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio-2.78
Price to Book (P/B)6.29
Price to Sales (P/S)2.43
P/FCF Ratio18.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€413.19Price Target Upside29.94% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)21.34
Revenue Forecast (FY)€2.36B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained, high free cash flow relative to earnings provides durable flexibility to fund capex, tuck-in acquisitions, franchise buybacks, and shareholder returns while absorbing reimbursement volatility. Strong cash conversion supports capital allocation even with cyclical swings.
Conservative Balance SheetLow leverage and high returns on equity give the company room to invest, pursue accretive franchise repurchases, and withstand episodic shocks (weather, regulatory). Conservative capital structure preserves strategic optionality and reduces refinancing and solvency risk.
VITAS Structural Growth & GuidanceVITAS is driving upgraded company guidance via higher admissions, better revenue/day, and margin improvement. Given aging demographics and referral networks, stronger VITAS fundamentals increase predictable cash flows and reduce reliance on cyclical plumbing services.
Bears Say
Roto-Rooter Margin PressureSustained higher paid-lead and marketing investment is compressing Roto-Rooter margins and could persist as competition and lead costs remain elevated. Structural margin pressure in a high-fixed-cost service network undermines consolidated profitability absent sustained ticket or efficiency gains.
VITAS Mix & Medicare Cap RiskShifts to shorter stays and lower acuity reduce revenue per admission and magnify sensitivity to Medicare reimbursement changes. This structural mix trend can lower long-term revenue growth and margins unless offset by higher admissions or favorable payor rates.
Governance/shareholder DissatisfactionA rejected say-on-pay indicates investor concern over executive compensation alignment and may prompt governance changes or activist scrutiny. Management distraction, policy revisions, or reputational impact could affect strategic execution and stakeholder trust.
CXM FAQ
What was Chemed’s price range in the past 12 months?
Chemed lowest stock price was €316.00 and its highest was €438.00 in the past 12 months.
What is Chemed’s market cap?
Chemed’s market cap is €5.70B.
When is Chemed’s upcoming earnings report date?
Chemed’s upcoming earnings report date is Jul 28, 2026 which is in 17 days.
How were Chemed’s earnings last quarter?
Chemed released its earnings results on Apr 23, 2026. The company reported €4.948 earnings per share for the quarter, beating the consensus estimate of €4.644 by €0.305.
Is Chemed overvalued?
According to Wall Street analysts Chemed’s price is currently Undervalued.
Does Chemed pay dividends?
Chemed does not currently pay dividends.
What is Chemed’s EPS estimate?
Chemed’s EPS estimate is 4.9.
How many shares outstanding does Chemed have?
Chemed has 13,274,104 shares outstanding.
What happened to Chemed’s price movement after its last earnings report?
Chemed reported an EPS of €4.948 in its last earnings report, beating expectations of €4.644. Following the earnings report the stock price went up 8.861%.
Which hedge fund is a major shareholder of Chemed?
Currently, no hedge funds are holding shares in DE:CXM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Chemed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€413.19 (29.94% Upside)
€413.19 (29.94% Upside)
Blogger Sentiment
Bullish
DE:CXM Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth €1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.56%
12-Months-Change
Fundamentals
Return on Equity
25.33%
Trailing 12-Months
Asset Growth
-11.05%
Trailing 12-Months
Company Description
Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
CXM Company Deck
CXM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong performance and outlook improvements driven primarily by VITAS — higher admissions, modest revenue and margin gains, a sizable addition to Florida cap cushion, and upward revisions to full-year ADC, revenue growth and adjusted EBITDA margin. Roto-Rooter showed early signs of stabilization in core residential services and strategic franchise acquisitions, but faces near-term headwinds: elevated paid marketing costs, weather-related lost revenue, water restoration pricing disruptions and a notable YoY decline in Roto-Rooter EBITDA and margins. On balance, VITAS’ outperformance and the company’s raised guidance outweigh Roto-Rooter’s challenges, producing a constructive overall view for the year while acknowledging execution risks at Roto-Rooter.View all DE:CXM earnings summariesCXM Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€413.19
▲(29.94% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Addus Homecare
―
Option Care Health
―
DaVita
―
National Healthcare
―
The Ensign Group
―
Options Prices
Currently, No data available
---










